Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, have been identified in several neoplastic diseases. Rearranged ALK is a driver of tumorigenesis, which activates various signaling pathway associated with proliferation and survival. To date, several agents that...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiełbowski, Kajetan, Żychowska, Justyna, Becht, Rafał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634320/
https://www.ncbi.nlm.nih.gov/pubmed/37954850
http://dx.doi.org/10.3389/fphar.2023.1285374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634320/
https://www.ncbi.nlm.nih.gov/pubmed/37954850
http://dx.doi.org/10.3389/fphar.2023.1285374

Ejemplares similares